

Partnership. Innovation. Passion.

March 22, 2024

To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 To, The Manager – Listing, National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: GLS

Dear Sir/Madam,

<u>Sub: Disclosure pursuant to Regulation 31A of the Securities and Exchange Board of India</u> (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Pursuant to the share purchase agreement dated September 21, 2023 among the Company, Nirma Limited and Glenmark Pharmaceuticals Limited, the Company has submitted today i.e. March 22, 2024 an application for the reclassification of Glenmark Pharmaceuticals Limited and Mr. Glenn Saldanha from 'promoter and promoter group' to 'public shareholders' to National Stock Exchange of India Limited and BSE Limited for their approval to approve such reclassification.

This is for your information and records.

Yours faithfully, For Glenmark Life Sciences Limited

Rudalf Corriea Company Secretary & Compliance Officer

Glenmark Life Sciences Limited

Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai 400 099, India. Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur - 413 213, India. T: 91 22 68297979 CIN: L74900PN2011PLC139963 E: complianceofficer@glenmarklifesciences.com W: www.glenmarklifesciences.com